Publications by Meesun Moon

Publications by authors named "Meesun Moon"

Gastric Cancer· January 2026

Social Media Activity not collected for this article yet.

Genomic Correlations for Clinical Outcomes in HER2-positive Advanced Gastric Cancer Treated Using Trastuzumab-based Therapy.

Sun Young Lee, Jaewon Hyung, Hyung-Don Kim, Hyungeun Lee, Meesun Moon

Anticancer Res· December 2025

Social Media Activity not collected for this article yet.

Predictive value of homologous recombination-related gene mutations in survival outcomes of first-line nivolumab plus chemotherapy for gastric cancer.

Yuna Lee, Hyung-Don Kim, Sun Young Lee, Hyungeun Lee, Jaewon Hyung, Meesun Moon

Gastric Cancer· November 2025

Social Media Activity not collected for this article yet.

Association between FGFR2b Positivity and Survival Outcomes of Patients with Gastric Cancer Treated with First-Line Nivolumab Plus Chemotherapy.

Hyung-Don Kim, Heonwoo Lee, Hyungeun Lee, Meesun Moon, Jaewon Hyung

Cancer Res Treat· November 2025

Social Media Activity not collected for this article yet.

Predictive value of EBV-positivity in patients with gastric cancer treated with first-line nivolumab plus chemotherapy.

Hyung-Don Kim, So-Yeon Kim, Hyungeun Lee, Yuna Lee, Jaewon Hyung, Meesun Moon

Gastric Cancer· July 2025

Social Media Activity not collected for this article yet.

Survival outcomes of patients with gastric cancer treated with first-line nivolumab plus chemotherapy based on claudin 18.2 expression.

Hyung-Don Kim, Jinho Shin, Jaewon Hyung, Hyungeun Lee, Meesun Moon

Gastric Cancer· January 2025

Social Media Activity not collected for this article yet.

GASTric Cancer HER2 Re-Assessment Study 2 (GASTHER2): HER2 Re-assessment for Initially HER2-Negative Advanced Gastric Cancer Patients after Progression on First-Line Treatment.

Jaewon Hyung, Hyung-Don Kim, Min-Hee Ryu, Young Soo Park, Meesun Moon

Cancer Res Treat· January 2024

Social Media Activity not collected for this article yet.

DNA mismatch repair deficiency and outcomes of patients with locally advanced gastric cancer treated with preoperative docetaxel, oxaliplatin, and S-1 plus surgery and postoperative S-1 or surgery plus postoperative S-1: a sub-analysis of the phase 3 PRODIGY trial.

Jaewon Hyung, Hyungwoo Cho, Hyung-Don Kim, Young Soo Park, Meesun Moon

Gastric Cancer· January 2024

Social Media Activity not collected for this article yet.

Association between HER2 heterogeneity and clinical outcomes of HER2-positive gastric cancer patients treated with trastuzumab.

Kyunghye Bang, Jaekyung Cheon, Young Soo Park, Hyung-Don Kim, Min-Hee Ryu, Meesun Moon

Gastric Cancer· July 2022

Social Media Activity not collected for this article yet.

Insertion-deletion rate is a qualitative aspect of the tumor mutation burden associated with the clinical outcomes of gastric cancer patients treated with nivolumab.

Hyung-Don Kim, Min-Hee Ryu, Young Soo Park, Sun Young Lee, Meesun Moon

Gastric Cancer· January 2022

Social Media Activity not collected for this article yet.

New prognostic model for patients with advanced gastric cancer: Fluoropyrimidine/platinum doublet for first-line chemotherapy.

Dong-Hoe Koo, Min-Hee Ryu, Mi-Yeon Lee, Mee-Sun Moon, Yoon-Koo Kang

World J Gastroenterol· December 2021

Social Media Activity not collected for this article yet.

Trends in Chemotherapy Patterns and Survival of Patients with Advanced Gastric Cancer over a 16-Year Period: Impact of Anti-HER2-Targeted Agent in the Real-World Setting.

Dong-Hoe Koo, Min-Hee Ryu, Mi-Yeon Lee, Heejung Chae, Eo Jin Kim, Mee-Sun Moon

Cancer Res Treat· April 2021

Social Media Activity not collected for this article yet.

Clinical implications of neutrophil-to-lymphocyte ratio and MDSC kinetics in gastric cancer patients treated with ramucirumab plus paclitaxel.

Hyung-Don Kim, Min-Hee Ryu, Sangsoon Yoon, Young-Soon Na, Meesun Moon

Chin J Cancer Res· October 2020

Social Media Activity not collected for this article yet.

Socials: